Jason Aryeh, Director at NOVELION THERAPEUTICS INC. (NVLN), bought 361 shares at $8.95 ($3K) on 2017-05-15, disclosed to the SEC on 2017-05-17.
Open-market purchase of $3k NVLN by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| OBIO | BUY | 2026-05-19 | $35K | — | Filing → |
| LGND | SELL | 2025-09-24 | $3.4M | — | Filing → |
| OBIO | BUY | 2025-09-19 | $2K | — | Filing → |